BioNotebook: Trevi, Complexa raise VC cash; Deerfield commits $60m to KemPharm; Aradigm, Voyager deal news; IPO updates
This article was originally published in Scrip
Executive Summary
The second quarter of 2014 started off with a surge in venture capital deals, but the momentum seems to have slowed a bit as the quarter gets closer to its end, with the exception of Trevi Therapeutics and Complexa, which recently announced a total of $38m in new capital.
You may also be interested in...
Finance Watch: Canaan Closes New VC Fund; CARB-X Backs More Antibiotics
Canaan raised $800m for tech and health care investments. Also, six companies closed VC rounds, CARB-X backed more antibiotics, CIRM funded BrainStorm and Sarepta led recent offerings.
Finance Watch VC Edition: Biopharma Venture Investment Rises In Second Quarter
Venture capital investment in biopharmaceutical firms for the first half of 2017 show that this year is on track to exceed 2016 levels. Recent financings include two $50m Series C rounds for two different companies developing later-stage drugs for itching: Trevi and Menlo Therapeutics.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.